Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 18, 2015

View Archived Issues

Topline results from exploratory study of Dextenza for inflammatory dry eye disease

Seres Therapeutics starts phase I trial of microbiome therapeutic SER-287 in UC

Pharnext begins phase III study of PXT-3003 for Charcot-Marie-Tooth disease type 1A

EPPS disaggregrates beta-amyloid plaques in mouse models of Alzheimer's disease

Bristol-Myers Squibb collaborates with UCLA within I-O RPM research program

Yisheng Biopharma collaborates with USAMRIID on Ebola vaccine

Novogene and Illumina to codevelop diagnostic for prenatal DNA and oncology testing in China

Chinese researchers report Nek2 inhibitor for gastrointestinal cancer

Phase III trial of KIT-302 meets primary efficacy endpoint

Rosetta and Biocept complete collaborative feasibility studies

Merck & Co. responds after conclusion of FDA advisory committee meeting on Vytorin

Sanford-Burnham Medical Research Institute introduces apelin receptor agonists

Cancer Research UK, Oregon Health & Science University collaborate on early cancer detection

Let-7g miRNA shows potential as a therapeutic target for hepatitis C

Athenex updates on its pipeline development and its acquisitions

StARD1 may be a novel therapeutic target for alcohol-driven liver disease

PEGylated rh arginase inhibits glioma cell growth

Oryzon Genomics files for clinical trial of ORY-2001 in Spain

Acerta reports results from phase I/II trial of acalabrutinib in relapsed CLL and SLL

Angiotensin AT2 receptor agonist prevents cancer cachexia in animal models

Helsinn's ghrelin receptor agonist HM-01 shows activity in preclinical models of cancer cachexia

ARQ-087 receives FDA orphan drug designation for cholangiocarcinoma

Isis Pharmaceuticals confirms initiation of phase II study of ISIS-TTR-Rx

Biogen patents autotaxin inhibitors

AstraZeneca acquires ZS Pharma

Imlygic approved in E.U. for unresectable melanoma that is distantly or regionally metastatic

Bridion from Merck & Co. receives approval for the reversal of neuromuscular blockade

CareDx to acquire transplantation diagnostics company Allenex

FDA approves Tris Pharma's extended-release chewable tablet formulation

OXiGENE's OXi-4503 receives E.U. orphan drug designation for AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...